Author

Elisabeth Heßmann

Universitätsmedizin GöttingenORCID 0000-0002-9462-1291Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 4 Research Focus:cell signaling & trafficking· 2 Research Focus:differential expression· 2 Research Focus:gene regulatory network inference· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

Günter SchneideriD· 2 shared Adi Danieli‐MackayiD· 1 shared Alexander KlegeriD· 1 shared Alexander Schramm· 1 shared Anna K. Baginska· 1 shared Anne Petzold· 1 shared Anton LahuseniD· 1 shared Argyris PapantonisiD· 1 shared

Activity by Year

2024-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Günter SchneiderORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Loss of the Y chromosome drives basal identity and metastatic potential via epigenetic reprogramming in pancreatic cancer

Madeleine Dorsch, Felix E.G. Beaudry, Anna K. Baginska, Nancy Meyer, Anne Petzold, Peihua Zhao, Belen Otero-Carrasco, Kazeera Aliar, Sebastian Urban, Julia Zummack, Jiwon Jung, Johanna Maria Hölken, Ningjun Duan, Laura Godfrey, Mei-Ju May Chen, , Barbara M. Grüner

This study identifies LOY as a driver of aggressive PDAC through epigenetic reprogramming, linking it to EMT and metastasis, and highlights its clinical relevance as a biomarker.

bioRxiv · Oct 8, 2026 · PreprintCancer Biology

Novel peptide targeting CXCR4 disrupt tumor-stroma crosstalk to eliminate migrating cancer stem cells

Kanishka Tiwary, Anton Lahusen, Syeda Inaas, Bastian Beitzinger, Roman Schmid, Mirja Harms, Stefanie Hauff, Frank Arnold, Karolin Walter, Sonia Alcalá, Stephan A. Hahn, Elisabeth Heßmann, Alexander Kleger, Ninel Azoitei, Thomas Theodor Werner Seufferlein, , Patrick Christian Hermann

This study identifies a CXCL12/CXCR4/BMI1 signaling axis that promotes metastasis in PDAC via tumor-stroma crosstalk and shows that JM#21, a CXCR4 inhibitor, suppresses miCSCs and enhances chemotherapy efficacy.

bioRxiv · Mar 3, 2025 · PreprintCancer Biology

Simultaneous Targeting of KRAS and CDK4 Synergistically Suppresses Pancreatic Cancer Cells

Maj-Britt Paulsohn, Klara Henrike Frahnert, Xin Fang, Carolin Schneider, Constanza Tapia Contreras, Günter Schneider, Elisabeth Heßmann, Matthias Dobbelstein

This study shows that combining KRAS and CDK4/6 inhibitors synergistically suppresses pancreatic cancer cells and organoids with KRAS mutations, with durable effects even after drug washout.

bioRxiv · Jan 11, 2025 · PreprintCancer Biology

A single-cell strategy for the identification of intronic variants related to mis-splicing in pancreatic cancer

Emre Taylan Duman, Maren Sitte, Karly Conrads, Adi Danieli‐Mackay, Fabian Ludewig, Philipp Ströbel, Volker Ellenrieder, Elisabeth Heßmann, Argyris Papantonis, Gabriela Salinas

The paper develops a single-nucleus full-length RNA-sequencing approach to identify intronic variants linked to mis-splicing in pancreatic cancer.

NAR Genomics and Bioinformatics · Apr 4, 2024Peer-reviewedGenomics